GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharos IBio Co Ltd (XKRX:388870) » Definitions » Financial Strength

Pharos IBio Co (XKRX:388870) Financial Strength : 8 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Pharos IBio Co Financial Strength?

Pharos IBio Co has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.

Good Sign:

Pharos IBio Co Ltd shows strong financial strength.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Pharos IBio Co did not have earnings to cover the interest expense. As of today, Pharos IBio Co's Altman Z-Score is 0.00.


Competitive Comparison of Pharos IBio Co's Financial Strength

For the Biotechnology subindustry, Pharos IBio Co's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharos IBio Co's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharos IBio Co's Financial Strength distribution charts can be found below:

* The bar in red indicates where Pharos IBio Co's Financial Strength falls into.



Pharos IBio Co Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Pharos IBio Co's Interest Expense for the months ended in Mar. 2024 was ₩-2.01 Mil. Its Operating Income for the months ended in Mar. 2024 was ₩-3,534.83 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩84.60 Mil.

Pharos IBio Co's Interest Coverage for the quarter that ended in Mar. 2024 is

Pharos IBio Co did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Pharos IBio Co's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Mar. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(154.806 + 84.602) / 0
=N/A

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Pharos IBio Co has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharos IBio Co  (XKRX:388870) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Pharos IBio Co has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.


Pharos IBio Co Financial Strength Related Terms

Thank you for viewing the detailed overview of Pharos IBio Co's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharos IBio Co (XKRX:388870) Business Description

Traded in Other Exchanges
N/A
Address
427beon-gil, Dongan-gu, 1407 and 1408, 38, Heungan-daero, Seongji Star With, Gyeonggi-do, Gwanyang-dong, Anyang-si, KOR
Pharos IBio Co Ltd is a company specializing in new drug development that develops treatments for rare and intractable diseases. It utilizes a new drug development platform based on big data and AI technology. Its product candidate comprises PHI-101-AML, a treatment drug for refractory/relapsed acute myeloid leukemia; PHI-101-OC developed for platinum-resistant/refractory ovarian cancer patients; PHI-101-TNBC is being developed as a drug to treat metastatic triple-negative breast cancer (TNBC); PHI-201; PHI-301; and PHI-501.

Pharos IBio Co (XKRX:388870) Headlines

No Headlines